Chai Discovery has recently completed a $130 million Series B funding round, elevating its valuation to $1.3 billion just months after its stealth launch. Co-led by Oak HC/FT and General Catalyst, this investment underscores the strength of Chai’s innovative AI models, which accurately predict biochemical interactions and design drugs for challenging “undruggable” targets. With support from heavyweights like OpenAI and Thrive Capital, Chai aims to revolutionize drug development, transforming it from a lengthy, unpredictable process into a streamlined, engineering-focused approach. The company’s advanced models exhibit remarkable efficiency, solving problems that previously took years in mere weeks. Chai’s recently unveiled Chai 2 platform, achieving significant breakthroughs in antibody design, demonstrates its potential to tackle complex pharmaceutical challenges. The new funding, now totaling over $225 million, will further accelerate Chai’s mission to create a comprehensive “computer-aided design suite,” poised to redefine biopharmaceutical development.
Source link
